CeriBell, Inc. $CBLL Shares Newly Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new position in shares of CeriBell, Inc. (NASDAQ:CBLL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 183,110 shares of the company’s stock, valued at approximately $4,466,000.

Several other hedge funds also recently added to or reduced their stakes in CBLL. Legal & General Group Plc acquired a new position in shares of CeriBell in the 2nd quarter worth approximately $53,000. State of Wyoming purchased a new stake in shares of CeriBell during the 1st quarter worth $62,000. Quantbot Technologies LP acquired a new position in shares of CeriBell during the 2nd quarter worth about $112,000. Y Intercept Hong Kong Ltd acquired a new stake in CeriBell during the first quarter worth approximately $341,000. Finally, Principal Financial Group Inc. increased its position in shares of CeriBell by 71.9% during the first quarter. Principal Financial Group Inc. now owns 23,180 shares of the company’s stock worth $425,000 after purchasing an additional 9,696 shares in the last quarter.

CeriBell Stock Up 1.2%

Shares of CeriBell stock opened at $27.80 on Thursday. The business has a 50-day moving average price of $25.46 and a 200 day moving average price of $21.00. CeriBell, Inc. has a fifty-two week low of $12.36 and a fifty-two week high of $28.89. The firm has a market cap of $1.08 billion, a P/E ratio of -14.33 and a beta of 0.86. The company has a quick ratio of 7.79, a current ratio of 8.18 and a debt-to-equity ratio of 0.17.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. The business had revenue of $29.34 million for the quarter, compared to the consensus estimate of $29.18 million. On average, sell-side analysts forecast that CeriBell, Inc. will post -2.05 earnings per share for the current fiscal year.

Insider Activity

In other news, VP David Foehr sold 9,255 shares of CeriBell stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total value of $224,433.75. Following the transaction, the vice president owned 34,144 shares of the company’s stock, valued at $827,992. The trade was a 21.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Xingjuan Chao sold 20,846 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $25.03, for a total value of $521,775.38. Following the completion of the transaction, the chief executive officer directly owned 746,345 shares in the company, valued at $18,681,015.35. This represents a 2.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 176,897 shares of company stock worth $4,415,969 over the last ninety days. 17.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CBLL shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. BTIG Research reaffirmed a “buy” rating on shares of CeriBell in a research note on Wednesday, November 4th. TD Cowen lifted their target price on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Canaccord Genuity Group raised their target price on shares of CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Finally, Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.25.

CeriBell Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.